AU2019240200B2 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations Download PDF

Info

Publication number
AU2019240200B2
AU2019240200B2 AU2019240200A AU2019240200A AU2019240200B2 AU 2019240200 B2 AU2019240200 B2 AU 2019240200B2 AU 2019240200 A AU2019240200 A AU 2019240200A AU 2019240200 A AU2019240200 A AU 2019240200A AU 2019240200 B2 AU2019240200 B2 AU 2019240200B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019240200A
Other languages
English (en)
Other versions
AU2019240200A1 (en
Inventor
Stephane FERRETTI
Nelson GUERREIRO
Ensar HALILOVIC
Sebastien Jeay
Astrid JULLION
Jinsheng Liang
Christophe MEILLE
Hui-qin WANG
Jens WUERTHNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2019240200A1 publication Critical patent/AU2019240200A1/en
Application granted granted Critical
Publication of AU2019240200B2 publication Critical patent/AU2019240200B2/en
Priority to AU2022209328A priority Critical patent/AU2022209328A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2019240200A 2018-03-20 2019-03-18 Pharmaceutical combinations Ceased AU2019240200B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022209328A AU2022209328A1 (en) 2018-03-20 2022-07-28 Pharmaceutical combinations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645754P 2018-03-20 2018-03-20
US62/645,754 2018-03-20
PCT/IB2019/052166 WO2019180576A1 (en) 2018-03-20 2019-03-18 Pharmaceutical combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022209328A Division AU2022209328A1 (en) 2018-03-20 2022-07-28 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
AU2019240200A1 AU2019240200A1 (en) 2020-09-10
AU2019240200B2 true AU2019240200B2 (en) 2022-07-21

Family

ID=66251830

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019240200A Ceased AU2019240200B2 (en) 2018-03-20 2019-03-18 Pharmaceutical combinations
AU2022209328A Abandoned AU2022209328A1 (en) 2018-03-20 2022-07-28 Pharmaceutical combinations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022209328A Abandoned AU2022209328A1 (en) 2018-03-20 2022-07-28 Pharmaceutical combinations

Country Status (14)

Country Link
US (1) US20210363254A1 (https=)
EP (1) EP3768717A1 (https=)
JP (2) JP2021518348A (https=)
KR (1) KR20200134253A (https=)
CN (1) CN111868088A (https=)
AU (2) AU2019240200B2 (https=)
BR (1) BR112020018755A2 (https=)
CA (1) CA3092307A1 (https=)
CL (1) CL2020002379A1 (https=)
IL (1) IL277334A (https=)
MX (1) MX2020009614A (https=)
RU (1) RU2020133811A (https=)
TW (1) TWI791794B (https=)
WO (1) WO2019180576A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017019896A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2017037579A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US20200261573A1 (en) * 2015-12-17 2020-08-20 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
WO2018185135A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017019896A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1

Also Published As

Publication number Publication date
JP2024012300A (ja) 2024-01-30
CA3092307A1 (en) 2019-09-26
RU2020133811A3 (https=) 2022-04-20
EP3768717A1 (en) 2021-01-27
AU2022209328A1 (en) 2022-10-20
RU2020133811A (ru) 2022-04-20
KR20200134253A (ko) 2020-12-01
AU2019240200A1 (en) 2020-09-10
IL277334A (en) 2020-10-29
BR112020018755A2 (pt) 2021-01-05
TWI791794B (zh) 2023-02-11
US20210363254A1 (en) 2021-11-25
WO2019180576A1 (en) 2019-09-26
CN111868088A (zh) 2020-10-30
CL2020002379A1 (es) 2021-03-05
TW201945001A (zh) 2019-12-01
JP2021518348A (ja) 2021-08-02
MX2020009614A (es) 2020-10-07

Similar Documents

Publication Publication Date Title
AU2017279046B2 (en) Therapeutic uses of a c-Raf inhibitor
KR102892725B1 (ko) 인간 넥틴4에 특이적인 항체
US20230119066A1 (en) Anti-ccr8 antibodies for treating cancer
US11001628B2 (en) Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
AU2015209145B2 (en) Antibody molecules to PD-1 and uses thereof
US20180177872A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
KR20180048684A (ko) 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민
KR20210117277A (ko) 인간 넥틴-2에 특이적인 항체
CN116059341A (zh) 药物组合物及用途
AU2022209328A1 (en) Pharmaceutical combinations
CN108697794A (zh) C-met抑制剂和抗pd-1抗体分子的组合及其用途
WO2022156726A1 (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
RU2825839C2 (ru) Антитела, специфичные к нектину-4 человека
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
HK40103924A (zh) 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法
HK40089230A (zh) 药物组合物及用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired